Business mix
- It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
- The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles.
- It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
Current key questions
- Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
- How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
- Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
